- States in Colorado and Arizona are competing on reproductive healthcare policy.
- State-level restrictions are limiting the Food and Drug Administration's access to reproductive healthcare information in Arizona, prompting legal challenges.
The FDA is facing actions seeking to revoke mifepristone's approval, challenging the mail-order policy, and pausing related lawsuits.
1 report, 1 independent
Updated Sep 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is facing actions seeking to revoke mifepristone's approval, challenging the mail-order policy, and pausing related lawsuits.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Louisiana is suing the FDA over telehealth abortions, and Liz Murrill is challenging the FDA's removal of in-person requirement.Sub-event
Lawsuits challenge mifepristone access due to state laws.1 source
Keep exploring
The entities involved
- FDA
-
Center for Reproductive Rights
advocacy organization that seeks to advance reproductive rights based in NYC
Nothing else this week.
-
Louisiana
state of the United States of America
Related events
- The FDA is facing actions seeking to revoke mifepristone's approval, challenging the mail-order policy, and pausing related lawsuits.
- The FDA is currently reviewing concerns regarding mail-order abortion pills and the circulation of mifepristone.
- The FDA has issued orders concerning the court jurisdiction matter involving Minnesota.
- A lawsuit has emerged challenging the state of Oklahoma regarding abortion bans, involving the Center for Reproductive Rights.
- FDA approval status impacts state medical procedures governed by Missouri law, affecting clinics like Planned Parenthood.